PHARMACOKINETICS OF A SINGLE ORAL DOSE OF LOMEFLOXACIN IN HEALTHY ELDERLY VOLUNTEERS

被引:9
作者
CROME, P
MORRISON, PJ
机构
[1] Department of Medicine for Elderly People, Orpington Hospital, Orpington, Kent, BR6 9JU, Sevenoaks Road
[2] Guys Drug Research Unit, London
来源
DRUG INVESTIGATION | 1991年 / 3卷 / 03期
关键词
D O I
10.1007/BF03259562
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of lomefloxacin 200 and 400mg, administered orally, were examined in 12 healthy elderly (between 65 and 85 years of age) subjects of both sexes. The drug was well tolerated by all subjects at both doses. Mean C(max) following the 200mg dose was 2.40 mg/L and the mean t(max) was 0.96 hours. Plasma half-life averaged 8.54 hours. Following the 400mg dose, the mean C(max) was 4.48 mg/L, the mean t(max) was 1.31 hours, and the mean plasma half-life was 8.75 hours. Mean urinary excretion rates were highest in the 0 to 4-hour interval after administration for both doses. Mean cumulative urinary excretion, as a percentage of dose, was similar for both doses. Plasma clearance averaged 146.9 ml/min and 143 ml/min for the 200 and 400mg doses, respectively. Renal clearances averaged 100.9 and 84.3 ml/min for the 200 and 400mg doses, respectively. These values were compared to data after single and multiple doses in male volunteers aged 18 to 45. The changes in clearance values observed in our study compared with those in younger subjects were not of sufficient magnitude to warrant reduced dosage in elderly individuals whose renal function is considered adequate for their age.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 9 条
[1]  
Ball A.P., Fox C., Ball M.E., Brown I.R.F., Willis J.V., Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients, Journal of Antimicrobial Chemotherapy, 17, pp. 629-635, (1986)
[2]  
Bayer A., Gajewska A., Stephens M., Stark M.J., Pathy J., Pharmacokinetics of ciprofloxacin in the elderly, Respiration, 51, pp. 292-295, (1987)
[3]  
Chin N-X, Novelli A., Neu H.C., In vitro activity of lomefloxacin (SC-47111, NY-198), a difluoroquinolone-3-carboxylic acid, compared with those of other quinolones, Antimicrobial Agents and Chemotherapy, 32, pp. 656-662, (1988)
[4]  
Dobbs B.R., Gazely L.R., Campbell A.J., Edwards I.R., The effect of age on the pharmacokinetics of enoxacin, European Journal of Clinical Pharmacology, 33, pp. 101-104, (1987)
[5]  
Lebel M., Bergeron M.G., Pharmacokinetics in the elderly, American Journal of Medicine, 82, pp. 108-114, (1987)
[6]  
Morrison P.J., Mant T.G.K., Norman G.T., Robinson J., Kunka R.L., Pharmacokinetics and tolerance of lomefloxacin after sequential increasing oral doses, Antimicrobial Agents and Chemotherapy, 32, pp. 1503-1507, (1988)
[7]  
Okezaki E., Makino E., Ohmichi K., Nagata O., Yamada T., Et al., Disposition and metabolism of NY-198, II: HPLC and bioassay studies of absorption and excretion in the dog, Chemotherapy (Tokyo), 16, pp. 138-143, (1988)
[8]  
Shock N.W., Watkin D.M., Yiengst B.S., Nor A.H., Gaffney G.W., Et al., Age differences in the water content of the body as related to basal oxygen consumption in males, Journal of Gerontology, 18, pp. 1-8, (1963)
[9]  
Wise R., Andrews J.M., Ashby J.P., Matthews R.S., In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents, Antimicrobial Agents and Chemotherapy, 32, pp. 617-622, (1988)